http://www.perilip.org About paper and industrial essay Share ideas Sat, 09 Jan 2010 19:11:24 +0000 en hourly 1 http://wordpress.org/?v=3.2.1 http://www.perilip.org/pharmaceutical-industry-innovation http://www.perilip.org/pharmaceutical-industry-innovation#comments Wed, 02 Dec 2009 12:31:12 +0000 http://www.perilip.org/pharmaceutical-industry-innovation According to Zucker, in biotech and pharmaceutical industry proximity to potential knowledge-assets and opportunities for commercialization constitutes s a great stimulus to entrepreneurship, especially around “star” scientists or entrepreneurs. In the interdisciplinary study Brewer provides evidence that mentioned inter-organizational alliances differ from traditional hierarchical relationships, because exchanges are external to the companies, and simultaneously those exchanges constitute not only market relationships. Practically, legal contracting constitutes only a part of such Read more

Here is no comments yet by the time your rss reader get this, Do you want to be the first commentor? Hurry up]]> According to Zucker, in biotech and pharmaceutical industry proximity to potential knowledge-assets and opportunities for commercialization constitutes s a great stimulus to entrepreneurship, especially around “star” scientists or entrepreneurs. In the interdisciplinary study Brewer provides evidence that mentioned inter-organizational alliances differ from traditional hierarchical relationships, because exchanges are external to the companies, and simultaneously those exchanges constitute not only market relationships. Practically, legal contracting constitutes only a part of such Read more

Here is no comments yet by the time your rss reader get this, Do you want to be the first commentor? Hurry up ]]> http://www.perilip.org/pharmaceutical-industry-innovation/feed 0 http://www.perilip.org/important-issues-in-pharmaceutical-industry http://www.perilip.org/important-issues-in-pharmaceutical-industry#comments Wed, 02 Dec 2009 11:31:23 +0000 http://www.perilip.org/important-issues-in-pharmaceutical-industry Many of the strongest European pharmaceutical firms adopted this strategy, seeking to develop their own capabilities across a relatively narrow front while working with biotech startups. The small, university-linked biotechs were at first almost entirely an American phenomenon, and this gave the large U.S. pharmaceutical companies an initial advantage, as did the federal government’s support for basic research in molecular genetics. But soon, European governments were attempting to close the widening biotech gap, hoping that government support would make up for the venture capital Read more

Here is no comments yet by the time your rss reader get this, Do you want to be the first commentor? Hurry up]]> Many of the strongest European pharmaceutical firms adopted this strategy, seeking to develop their own capabilities across a relatively narrow front while working with biotech startups. The small, university-linked biotechs were at first almost entirely an American phenomenon, and this gave the large U.S. pharmaceutical companies an initial advantage, as did the federal government’s support for basic research in molecular genetics. But soon, European governments were attempting to close the widening biotech gap, hoping that government support would make up for the venture capital Read more

Here is no comments yet by the time your rss reader get this, Do you want to be the first commentor? Hurry up ]]> http://www.perilip.org/important-issues-in-pharmaceutical-industry/feed 0 http://www.perilip.org/managing-innovation-and-change-case-of-pharmaceutical-industry http://www.perilip.org/managing-innovation-and-change-case-of-pharmaceutical-industry#comments Wed, 02 Dec 2009 11:02:59 +0000 http://www.perilip.org/managing-innovation-and-change-case-of-pharmaceutical-industry In contemporary context, the pharmaceutical and biotechnology sectors are characterised by a high level of competition and innovation. Some fifteen or twenty years ago biotechnology, which was heavily depended on advances in molecular biology, and pharmaceuticals, which was predominantly based on microbiology and chemistry, were widely recognized as separate industries. However, now biotechnology and pharmaceutical companies are significantly interconnected and are evolving into complex systems, representing particular innovation networks. The transformation from an old to a new Read more

Here is no comments yet by the time your rss reader get this, Do you want to be the first commentor? Hurry up]]> In contemporary context, the pharmaceutical and biotechnology sectors are characterised by a high level of competition and innovation. Some fifteen or twenty years ago biotechnology, which was heavily depended on advances in molecular biology, and pharmaceuticals, which was predominantly based on microbiology and chemistry, were widely recognized as separate industries. However, now biotechnology and pharmaceutical companies are significantly interconnected and are evolving into complex systems, representing particular innovation networks. The transformation from an old to a new Read more

Here is no comments yet by the time your rss reader get this, Do you want to be the first commentor? Hurry up ]]> http://www.perilip.org/managing-innovation-and-change-case-of-pharmaceutical-industry/feed 0 http://www.perilip.org/innovation-and-change-in-pharmaceutical-industry http://www.perilip.org/innovation-and-change-in-pharmaceutical-industry#comments Wed, 02 Dec 2009 09:32:55 +0000 http://www.perilip.org/innovation-and-change-in-pharmaceutical-industry Achilladelis and Antonakis conducted a historical study of the dynamics and tendencies of technological innovation in the pharmaceutical industry. From this standpoint, pursuing increase in market share, major pharma companies undertake mergers and acquisitions. As the majority of specialists points out, particularly mergers and acquisitions are considered to be essential ways to obtain innovation capabilities and assuming control levers of any major technological changes within biotech industry. For instance, in the beginning of 90s, Swiss pharmaceutical giant Hoffmann-La Roche after Read more

Here is no comments yet by the time your rss reader get this, Do you want to be the first commentor? Hurry up]]> Achilladelis and Antonakis conducted a historical study of the dynamics and tendencies of technological innovation in the pharmaceutical industry. From this standpoint, pursuing increase in market share, major pharma companies undertake mergers and acquisitions. As the majority of specialists points out, particularly mergers and acquisitions are considered to be essential ways to obtain innovation capabilities and assuming control levers of any major technological changes within biotech industry. For instance, in the beginning of 90s, Swiss pharmaceutical giant Hoffmann-La Roche after Read more

Here is no comments yet by the time your rss reader get this, Do you want to be the first commentor? Hurry up ]]> http://www.perilip.org/innovation-and-change-in-pharmaceutical-industry/feed 0 http://www.perilip.org/innovation-in-pharmaceutical-industry http://www.perilip.org/innovation-in-pharmaceutical-industry#comments Wed, 02 Dec 2009 08:43:34 +0000 http://www.perilip.org/innovation-in-pharmaceutical-industry One of the biotechs was Repligen, a Cambridge, Massachusetts, firm (founded in 1981) that specialized in efforts to develop treatments for cancer and inflammation, as well as AIDS. Typical in several regards of the new pattern of R&D was the experience of the Merck Research Laboratories (MRL). While pursuing in-house research, the firm also worked with two biotech companies on alternative approaches to HIV prevention with a vaccine or treatment. Later, Merck collaborated with MedImmune, Inc., a Maryland biotech, in an attempt to use that firm’s monoclonal antibodies as a means of Read more

Here is no comments yet by the time your rss reader get this, Do you want to be the first commentor? Hurry up]]> One of the biotechs was Repligen, a Cambridge, Massachusetts, firm (founded in 1981) that specialized in efforts to develop treatments for cancer and inflammation, as well as AIDS. Typical in several regards of the new pattern of R&D was the experience of the Merck Research Laboratories (MRL). While pursuing in-house research, the firm also worked with two biotech companies on alternative approaches to HIV prevention with a vaccine or treatment. Later, Merck collaborated with MedImmune, Inc., a Maryland biotech, in an attempt to use that firm’s monoclonal antibodies as a means of Read more

Here is no comments yet by the time your rss reader get this, Do you want to be the first commentor? Hurry up ]]> http://www.perilip.org/innovation-in-pharmaceutical-industry/feed 0